{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:47:47Z","timestamp":1794635267695,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074142"],"award-info":[{"award-number":["72074142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-026-00827-8","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:19:12Z","timestamp":1784963952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Value-based price corridor for bepirovirsen in chronic hepatitis B: an early health technology assessment in a cost-compressed setting"],"prefix":"10.1186","volume":"16","author":[{"given":"Kaijie","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"827_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: A review. JAMA. 2018;319:1802. https:\/\/doi.org\/10.1001\/jama.2018.3795.","journal-title":"JAMA"},{"key":"827_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5501\/wjv.v11.i1.57","volume":"11","author":"W Leowattana","year":"2022","unstructured":"Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol. 2022;11:57\u201372. https:\/\/doi.org\/10.5501\/wjv.v11.i1.57.","journal-title":"World J Virol"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Buti M, Lampertico P, Lee HM. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D- report from the 2022 AASLD-EASL HBV\/HDV treatment endpoints conference. Hepatol Baltim Md. 2023;78:1654\u201373. https:\/\/doi.org\/10.1097\/HEP.0000000000000431.","journal-title":"Hepatol Baltim Md"},{"key":"827_CR4","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"M-F Yuen","year":"2022","unstructured":"Yuen M-F, Lim S-G, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387:1957\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2210027.","journal-title":"N Engl J Med"},{"issue":"24","key":"827_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","volume":"394","author":"J Hou","year":"2026","unstructured":"Hou J, Lim S-G, Buti M, Yuen M-F. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med. 2026;394(24):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa2515131.","journal-title":"N Engl J Med"},{"key":"827_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/liv.15027","volume":"42","author":"M Toy","year":"2022","unstructured":"Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud M-C, et al. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and australia. Liver Int Off J Int Assoc Study Liver. 2022;42:16\u201325. https:\/\/doi.org\/10.1111\/liv.15027.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"827_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-2024-754","volume":"14","author":"R Yan","year":"2025","unstructured":"Yan R, Sun M, Yang H, Du S, Sun L, Mao Y. 2024 latest report on hepatitis B virus epidemiology in China: Current status, changing trajectory, and challenges. Hepatobiliary Surg Nutr. 2025;14:66\u201377. https:\/\/doi.org\/10.21037\/hbsn-2024-754.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"842944","DOI":"10.3389\/fphar.2022.842944","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Lu ZK, Xiong X, Lee T-Y, Huang H, Jiang B. Impact of national volume-based procurement on the procurement volumes and spending for antiviral medications of hepatitis B virus. Front Pharmacol. 2022;13:842944. https:\/\/doi.org\/10.3389\/fphar.2022.842944.","journal-title":"Front Pharmacol"},{"key":"827_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the national institute for health and care excellence cost-effectiveness threshold. Health Technol Assess Winch Engl. 2015;19:1\u2013vi. https:\/\/doi.org\/10.3310\/hta19140.","journal-title":"Health Technol Assess Winch Engl"},{"key":"827_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: Initial estimates and the need for further research. Value Health. 2016;19:929\u201335. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health"},{"key":"827_CR11","doi-asserted-by":"publisher","first-page":"e230090","DOI":"10.57264\/cer-2023-0090","volume":"13","author":"E Sinakos","year":"2024","unstructured":"Sinakos E, Kachru N, Tsoulas C, Jeyakumar S, Smith NJ, Yehoshua A, et al. Cost\u2013effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in greece. J Comp Eff Res. 2024;13:e230090. https:\/\/doi.org\/10.57264\/cer-2023-0090.","journal-title":"J Comp Eff Res"},{"key":"827_CR12","doi-asserted-by":"publisher","first-page":"e02694","DOI":"10.1128\/spectrum.02694-24","volume":"13","author":"H Liang","year":"2025","unstructured":"Liang H, Zheng X, Mao Q, Yang J, Ruan Q, Wu C. Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients. Microbiol Spectr. 2025;13:e02694\u201324. https:\/\/doi.org\/10.1128\/spectrum.02694-24.","journal-title":"Microbiol Spectr"},{"key":"827_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","volume":"13","author":"B Wu","year":"2010","unstructured":"Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: A markov analysis. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2010;13:592\u2013600. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00733.x.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"827_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2010;13:934\u201345. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00777.x.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"827_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/hep.23348","volume":"51","author":"Y-C Chen","year":"2010","unstructured":"Chen Y-C, Chu C-M, Liaw Y-F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatol Baltim Md. 2010;51:435\u201344. https:\/\/doi.org\/10.1002\/hep.23348.","journal-title":"Hepatol Baltim Md"},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3760\/cma.j.issn.1007-3418.2002.01.114","volume":"10","author":"G Wu","year":"2002","unstructured":"Wu G, Zhou W, Zhao Y, Guo S, Wang Z, Zou S, et al. Study on the natural history of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin. J Hepatol. 2002;10:46\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2002.01.114.","journal-title":"J Hepatol"},{"key":"827_CR17","doi-asserted-by":"publisher","unstructured":"Huang H, Zhu CW, Yu XF, Wang GS, Wang JY. The development of cirrhosis in Chinese patients with chronic hepatitis B. Chin Hepatol. 2007;12(6):437\u201340. https:\/\/doi.org\/10.3969\/j.ssn.1008-1704.2007.06.001.","DOI":"10.3969\/j.ssn.1008-1704.2007.06.001"},{"key":"827_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1046\/j.1440-1746.2003.03187.x","volume":"18","author":"B Xu","year":"2003","unstructured":"Xu B, Hu D-C, Rosenberg DM, Jiang Q-W, Lin X-M, Lu J-L, et al. Chronic hepatitis B: A long-term retrospective cohort study of disease progression in shanghai, China. J Gastroenterol Hepatol. 2003;18:1345\u201352. https:\/\/doi.org\/10.1046\/j.1440-1746.2003.03187.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"827_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0168-8278(03)00139-9","volume":"39","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39:51\u20138. https:\/\/doi.org\/10.1016\/S0168-8278(03)00139-9.","journal-title":"J Hepatol"},{"key":"827_CR20","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","volume":"20","author":"X Lin","year":"2005","unstructured":"Lin X, Robinson NJ, Thursz M, Rosenberg DM, Weild A, Pimenta JM, et al. Chronic hepatitis B virus infection in the asia-pacific region and africa: Review of disease progression. J Gastroenterol Hepatol. 2005;20:833\u201343. https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03813.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"827_CR21","unstructured":"China population census yearbook\u2009\u2013\u20092020. n.d. https:\/\/www.stats.gov.cn\/sj\/pcsj\/rkpc\/7rp\/zk\/indexce.htm."},{"key":"827_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","volume":"5","author":"UH Iloeje","year":"2007","unstructured":"Iloeje UH, Yang H-I, Jen C-L, Su J, Wang L-Y, You S-L, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:921\u201331. https:\/\/doi.org\/10.1016\/j.cgh.2007.06.015.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"827_CR23","doi-asserted-by":"publisher","first-page":"42253","DOI":"10.1038\/srep42253","volume":"7","author":"Q Ling","year":"2017","unstructured":"Ling Q, Dai H, Zhuang R, Shen T, Wang W, Xu X, et al. Predicting short-term survival after liver transplantation on eight score systems: A national report from China liver transplant registry. Sci Rep. 2017;7:42253. https:\/\/doi.org\/10.1038\/srep42253.","journal-title":"Sci Rep"},{"key":"827_CR24","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1245\/s10434-013-3023-5","volume":"20","author":"T-J Wu","year":"2013","unstructured":"Wu T-J, Chan K-M, Chou H-S, Lee C-F, Wu T-H, Chen T-C, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: The influence of viral characteristics on clinical outcome. Ann Surg Oncol. 2013;20:3582\u201390. https:\/\/doi.org\/10.1245\/s10434-013-3023-5.","journal-title":"Ann Surg Oncol"},{"key":"827_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2008;11:527\u201338. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00297.x.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"827_CR26","doi-asserted-by":"publisher","first-page":"e0162763","DOI":"10.1371\/journal.pone.0162763","volume":"11","author":"Y Liu","year":"2016","unstructured":"Liu Y, Zhang S, Zhao Y, Du J, Jin G, Shao S, et al. Development and application of the Chinese (mainland) version of chronic liver disease questionnaire to assess the health-related quality of life (HRQoL) in patients with chronic hepatitis B. PLoS ONE. 2016;11:e0162763. https:\/\/doi.org\/10.1371\/journal.pone.0162763.","journal-title":"PLoS ONE"},{"key":"827_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1477-7525-12-101","volume":"12","author":"G Zhuang","year":"2014","unstructured":"Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: A cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014;12:101. https:\/\/doi.org\/10.1186\/1477-7525-12-101.","journal-title":"Health Qual Life Outcomes"},{"key":"827_CR28","unstructured":"\u300aChina guidelines for pharmacoeconomic evaluation\u2009\u2013\u20092020\u300b. n.d. https:\/\/www.cpa.org.cn\/index.php?do=info&cid=75553"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00827-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00827-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00827-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:18:02Z","timestamp":1792549082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00827-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00827-8","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This simulation study did not involve identifiable personal medical information or animal subjects; ethics approval and consent to participate were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"122"}}